Compare HTFL & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | ATRC |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2025 | 2005 |
| Metric | HTFL | ATRC |
|---|---|---|
| Price | $48.49 | $56.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $38.20 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 2.1M | 835.6K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.37 | 74.74 |
| EPS | N/A | ★ 0.18 |
| Revenue | $176,034,000.00 | ★ $201,630,000.00 |
| Revenue This Year | $27.66 | $15.27 |
| Revenue Next Year | $23.55 | $12.21 |
| P/E Ratio | ★ N/A | $303.00 |
| Revenue Growth | ★ 39.92 | 15.40 |
| 52 Week Low | $20.13 | $25.36 |
| 52 Week High | $51.78 | $55.72 |
| Indicator | HTFL | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 78.90 |
| Support Level | $47.13 | $26.95 |
| Resistance Level | $51.48 | N/A |
| Average True Range (ATR) | 2.40 | 1.95 |
| MACD | -0.71 | 0.12 |
| Stochastic Oscillator | 64.86 | 97.56 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.